Answers are grounded in this paper and cite their sources.
Recently, there has been an increase in the use of targeted therapies for cancer treatments. Nevertheless, the ocular side-effects of the commonly used targeted agents are generally under-reported and not well studied in the literature. We conducted multiple searches in databases, including Medline, EMBASE, Cochrane Library and conference proceedings, using the following strings: ‘name of targeted therapeutic agent (both generic and commercial names)’ AND ‘eye OR ocular OR vision OR ophthalmological’. Various targeted agents have been found to be associated with ocular side-effects due to their specific targeting of activities in the eye. Imatinib commonly causes periorbital oedema, epiphora and occasionally conjunctival haemorrhage. Cetuximab causes corneal lesions, meibomian gland dysfunction, periorbital and lid dermatitis, blepharitis and conjunctivitis. Erlotinib is related to various ocular toxicities, mainly on the ocular surface, and perifosine has been reported to be associated with severe keratitis. Bevacizumab could potentially disrupt intrinsic ocular circulation and lead to the development of thromboembolic events; there are rare reported cases of optic neuritis or optic neuropathy. Other targeted agents, such as trastuzumab, sunitinib and crizotinib, also have specific ocular toxicities. In conclusion, ocular effects of targeted agents are not uncommon in cancer patients receiving targeted therapy. Ophthalmologists should have high indexes of suspicion to diagnose and treat these complications promptly. Within the ever-expanding armamentarium of anticancer agents, targeted therapy, with its robust activity and good tolerability, has emerged rapidly in the recent decades. According to the definition by the National Cancer Institute, targeted therapy is a type of anticancer treatment that blocks the growth of cancer cells by interfering with specific molecules that are needed for carcinogenesis and tumour growth (they are therefore more cancer specific) rather than attacking all rapidly dividing cells (e.g. as with traditional chemotherapy). Targeted cancer therapies may be more effective than other anticancer treatments and less harmful to normal cells. In the era of personalized medicine, more than 20 targeted agents have been approved for specific indications in cancer treatment; many more are in the early stages of clinical development. Most of these agents work through mechanisms markedly different from conventional chemotherapy by targeting cellular signalling and angiogenesis pathways, and they are associated with distinct adverse effects. The eye, with its high vascularity, rapid proliferation and abundant distribution of receptors for various signalling molecules, is particularly susceptible to the effects of targeted agents (Fig. 1). A Summary of the Distribution of Various Signalling Pathways in the Eye and the Related Targeted Agents. EGF, epidermal growth factor; mTOR, mammalian target of rapamycin; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; ALK, anaplastic lymphoma kinase. Although ocular toxicities associated with various anticancer treatments have been documented in the literature, nearly all reported toxicities are from radiotherapy, chemotherapy and hormonal therapies. There are only a few reports that specifically address the issue of ocular toxicities associated with the commonly used targeted therapies. Notably, with the increasing number of cancer patients receiving targeted treatment, ophthalmologists’ awareness of the potential ocular toxicities of these targeted agents is paramount to allow for timely management of cancer patients with ocular complaints. When a patient presents with a specific ocular symptom, it is important to delineate whether the complaints are due to the tumour itself, its associated effects, such as paraneoplastic syndrome, or the treatments. In this review, we summarize the reported ophthalmologic adverse effects of various commonly used targeted therapies in clinical practice. Imatinib (GleevecTM) is a selective inhibitor of Bcr-Abl, c-kit, Arg and platelet-derived growth factor receptor (PDGFR)-related protein tyrosine kinase (Fig. 1). It is approved for treatment of chronic myeloid leukaemia and gastrointestinal stromal tumours. It is associated with a number of known ocular side-effects. Periorbital oedema is the most common ocular side-effect associated with imatinib (Esmaeli et al. 2004; Dogan & Esmaeli 2009) reported in up to 70% of patients with gastrointestinal stromal tumours in a randomized multicentre trial (Demetri et al. 2002) and similarly in another retrospective series (Fraunfelder et al. 2003). This phenomenon is due to dermal dendrocytes found in the periocular soft tissue that express particular molecular targets of imatinib, namely c-kit and PDGFR. Through the inhibition of PDGFR, imatinib may decrease the interstitial pressure and increase trans-capillary transport (Pietras et al. 2001; Esmaeli et al. 2002). In the literature, most of the reported cases improved with topical steroids and systemic diuretics, but surgical procedures in the form of debulking excessive skin, fat and oedema were required occasionally (Esmaeli et al. 2004; McClelland et al. 2010). Epiphora, the second most common orbital complaint with imatinib, occurs in nearly 20% of patients (Fraunfelder et al. 2003; Esmaeli et al. 2004). Postulated mechanisms for epiphora include conjunctival chemosis resulting in ocular surface irritation and the overproduction of tears, lacrimal pump dysfunction due to periorbital oedema, blockage of the puncta by conjunctivochalasis and secretion of the medication in the tear film. Topical steroids and diuretics have been useful in these situations (Dogan & Esmaeli 2009). Haemorrhage in the conjunctiva, which is rich in c-kit-positive mast cells (Stahl et al. 1999), was also noted in 11% of patients in a cohort of 87 in the absence of marrow suppression or systemic bleeding tendency; drug hypersensitivity and ocular irritation were suggested as possible mechanisms. Most of these cases spontaneously improved or improved with topical steroids (Radaelli et al. 2007). Sight-threatening complications affecting the optic nerve, macula and retina are uncommon but do occur with imatinib. Imatinib was shown to compromise the survival of retinal ganglion cells in vitro via the inhibition of the PDGFR signalling pathway (Biswas et al. 2009). Full-thickness retinal necrosis, chronic nongranulomatous vitritis and retinal oedema have been demonstrated in rabbit eyes after an intravitreal injection of imatinib and subsequent enucleation; because of the unknown effects of imatinib at the blood-retinal barrier, the in vivo significance of this finding has not been determined (Kitzmann et al. 2008). A clinical case report described imatinib-induced optic disc oedema and optic nerve dysfunction as evidenced by visual field depression and prolongation of P100 latency, which regressed after the cessation of the medication (Kwon et al. 2008). Cases of recurrent optic neuritis (Govind Babu et al. 2007), cystoid macular oedema and retinal oedema related to imatinib (Masood et al. 2005) are also reported in the literature. The macular oedema and retinal oedema subsided with cessation of the medication, and optic neuritis improved with systemic steroids. Erlotinib (TarcevaTM) is a novel tyrosine kinase inhibitor that inhibits the activity of tyrosine kinase at the epidermal growth factor receptor (EGFR) and has been widely used to treat nonsmall-cell lung cancer and pancreatic cancer (Fig. 1). It shares a similar ocular toxicity profile with cetuximab, but its toxicities are mainly limited to the ocular surface. It has been reported to be associated with delayed corneal epithelial healing due to epidermal growth factor inhibition and possible secondary infectious keratitis (Johnson et al. 2009). Trichomegaly has also been documented as a side-effect of erlotinib, which may aggravate corneal epithelial damage. Epilation was used to treat the aforementioned problems (Lane & Goldstein 2007; Papadopoulos et al. 2008). Other reported ocular side-effects, including periorbital rash, swelling and secondary ectropion, improved after cessation of the medication (Methvin & Gausas 2007). Secondary conjunctivitis has been reported as another complication of ocular surface toxicity (2006). Gefitinib (Iressa TM) is another commonly used epidermal growth factor receptor inhibitor. It is mainly used for the treatment of nonsmall-cell lung cancer in Asian patients harbouring specific epidermal growth factor mutations. It has occasionally been associated with minor and treatable superficial punctate keratopathy, dry eyes, blepharitis, conjunctivitis and trichiasis. Fortunately, the conditions are usually mild and topical lubricants and antibiotics were usually sufficient for treatment (Tullo et al. 2005). Perifosine is a novel phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) inhibitor that inhibits Akt activation in the PI3K pathway and also affects a number of other key signal transduction pathways, including the c-Jun N-terminal kinase (JNK) pathway, all of which are associated with programmed cell death, cell growth, cell differentiation and cell survival (Fig. 1). Perifosine affects multiple pivotal signalling pathways, which therefore render this agent useful for various malignancies, such as refractory colorectal cancer and Waldenström’s macroglobulinemia. Regarding its ocular toxicities, there were reports of severe adverse effects in the form of keratitis presenting as peripheral, paralimbal, ring-shaped, superficial corneal stromal infiltration and corneal ulcers that resembled the features of autoimmune keratitis. The exact mechanism of keratitis has not been understood. As most of the reported cases of ulcerative keratitis were in patients who had been receiving imatinib, a possible synergistic toxicity has been postulated but not yet proven. This can be potentially sight threatening, but fortunately, most of the reported cases responded to topical steroids (Shome et al. 2008; Dogan & Esmaeli 2009; Keenan et al. 2010). Crizotinib, a novel anaplastic lymphoma kinase (ALK) inhibitor (Fig. 1) with robust activity against ALK-positive nonsmall-cell lung cancer in phase II trials, was recently reported to be associated with a light–dark accommodation abnormality without objective ophthalmological abnormalities in up to 42% of patients (Shaw et al. 2011). The mechanism for this phenomenon is not well understood. Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor used in the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumours (Fig. 1). It acts by working against platelet-derived growth factor receptors and vascular endothelial growth factor receptors. Similar to other anti-VEGFs, it is associated with cardiovascular disturbances. Cases have been reported regarding its role in reversible posterior leucoencephalopathy syndrome, which can cause cortical blindness that is reversible after the cessation of therapy and with blood pressure control (Chen & Agarwal 2009; Padhy et al. 2011). Ras-Raf-mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) kinase (MEK)-ERK cascade is a signal transduction pathway that is aberrantly activated in various neoplasms. Several agents have been developed to target this pathway. Although most of these agents have only been tested in clinical trials, ocular toxicities have already been reported. Ocular adverse effects (coloured spots or halos) have been observed in 34% of the patients receiving the MEK inhibitor PD0325901 at doses greater than 15 mg twice daily. Moreover, retinal vein occlusion has also been observed in three patients receiving PD0325901. Another MEK inhibitor, selumetinib, has been reported to cause blurring of vision, but symptoms gradually subsided after decreasing the dosage during the clinical trials. Similar complaints have been seen in patients on other MEK inhibitors, including GSK1120212 and AS703026. This unique toxicity associated with this class of drug suggests that it is an on-target, MEK-mediated effect (Sebolt-Leopold 2008; Delord et al. 2010; Infante et al. 2010). Cetuximab (ErbituxTM) is a chimeric monoclonal antibody against epidermal growth factor receptor (EGFR) whose downstream signalling pathways are essential for tumour survival and proliferation (Fig. 1). It is primarily approved for the treatment of metastatic colorectal carcinoma and head and neck squamous cell carcinoma. EGFR is expressed in various ocular structures, including hair follicles, meibomian glands and corneal, limbal, and conjunctival epithelium (Fig. 1). In hair follicles, the EGFR cascade regulates the transformation from anagen or the growth phase to catagen or the regressive phase. Cetuximab-induced inhibition of EGFR alters the growth cycle leading to abnormal hair growth and terminal differentiation (Vaccaro et al. 2009; Vano-Galvan et al. 2010). In addition, the keratinocyte architecture of root sheaths and the pattern of normal hair growth are affected, resulting in disoriented and short hair follicles. Because of the abnormal structures of these hairs, they may affect the corneal surface by causing local mechanical irritation (Dueland et al. 2003; Melichar & Nemcova 2007). Meibomian gland dysfunction with increased seborrheic secretions, periorbital and lid dermatitis, blepharitis and conjunctivitis were also reported (Tonini et al. 2005; Melichar & Nemcova 2007). Corneal epithelial toxicity has also been reported. EGFR in corneal, limbal and conjunctival epithelium stimulates epithelial proliferation, migration and wound healing; cetuximab causes a breakdown in this self-healing mechanism to the extent of persistent corneal erosion, despite all convention treatments, including lubrication, bandage lens and patching. In one reported case, topical epidermal growth factor administration was essential to improve the wound healing (Foerster et al. 2008; Forster et al. 2008). Although the ocular side-effects of cetuximab are apparently restricted to cutaneous structures and the major effects are mainly cosmetic and locally irritating, a potentially blinding keratopathy can be a serious sequel due to surface opacification after repeated erosion and scarring. Bevacizumab (AvastinTM) is a monoclonal antibody that binds to vascular endothelial growth factor-1 (VEGF-1) (Fig. 1) and is approved for use in metastatic colon cancer, nonsmall-cell lung cancer, renal cell cancer and glioblastoma multiforme. Additionally, bevacizumab is used as an off-label treatment for neovascular age-related macular degeneration. To date, there are no large-scale reports on the ocular side-effects of bevacizumab when used systemically. Bevacizumab infusion is associated with cerebral or cardiac ischaemic events (Klastersky 2006). Similarly, the eye can be affected by the disruption of the intrinsic ocular circulation or the development of thromboembolic events, although not yet reported in the literature. Interestingly, there were rare reported cases of optic neuritis and optic neuropathy associated with bevacizumab treatment for cutaneous melanoma and glioblastoma (Biswas et al. 2008; Sherman et al. 2009). Another case of an acute retinal pigment epithelial tear in the untreated fellow eye following bevacizumab injections was also reported, suspected to be caused by bevacizumab reaching the other eye via systemic circulation (Mennel et al. 2007). Of note, bevacizumab use is associated with the occurrence of reversible posterior leucoencephalopathy syndrome (RPLS), which may commonly present as cortical blindness (Allen et al. 2006; Glusker et al. 2006). Although the primary pathology of RPLS is not in the eye and ophthalmological examination is usually unremarkable, patients may first present to ophthalmologists complaining of visual disturbances. Other clinical features in this syndrome include hypertension, headache, seizures and altered mental status. The pathogenesis is attributed to vasogenic oedema from changes in blood pressure related to vasospasm or toxic damage to blood-brain barrier or vascular endothelium (Glusker et al. 2006). Diagnosis is made by magnetic resonance imaging (MRI), where bilateral grey and white matter oedema in the posterior regions of the cerebral hemispheres can be observed. Vision usually returns to baseline after blood pressure is controlled and bevacizumab is stopped. Trastuzumab (HerceptinTM) is a humanized monoclonal antibody that acts by binding to the extracellular juxtamembrane domain of human epidermal growth factor receptor type 2 (HER 2). By down-regulating downstream signalling cascades, trastuzumab is useful in inhibiting proliferation and the survival of HER2-dependent tumours, mainly breast cancer and advanced gastric cancer. In vivo, trastuzumab was found to inhibit corneal neovascularization, (Guler et al. 2009) but the ocular effects of trastuzumab in human subjects are not known. In a study on a related compound, trastuzumab-DM1, a HER2 antibody-cytotoxic conjugate, adverse ocular effects were reported to be 27.7% (Burris et al. 2011). These included dry eyes, increased lacrimation, mild subjective blurring of vision and conjunctivitis, and they were generally mild and tolerable. Targeted agents represent a promising treatment modality in cancer patients. Nonetheless, they are relatively new in clinical development, and their effects on normal tissues are not fully understood. The eye, a complex integration of the neurological, vascular and cutaneous systems, can be affected by these targeted agents (Table 1). Ocular complications have been studied for a few targeted agents but are likely to be under-reported in others with similar or overlapping actions. A high index of suspicion would facilitate a better understanding of the ophthalmic effects of these agents and the prevention of sight-threatening complications. Despite the diversity of ocular complications caused by various targeted agents, a simple screening protocol that consists of visual acuity, colour vision assessment, Amsler grid test, pupil reaction and fluorescein staining of the cornea surface may be helpful in high-risk patients. Assessments can be performed at the patient’s baseline and then regularly by trained nurses. Abnormal results may prompt the referral to an ophthalmologist. It is also important to address the optimal frequency of follow-up in these patients. Although a more frequent follow-up schedule is better for the earlier detection of complications, it might be difficult to implement in most centres. Baseline screening, as mentioned, and prompt referral for ophthalmological attention may be a compromised solution. Moreover, general toxicity scores and self-reported questionnaires might be used to facilitate the standardization of symptom reporting. More importantly, in patients on targeted therapies and at high risk for developing ocular side-effects, oncologists may consult the ophthalmologists about the need to prescribe prophylactic treatments, such as topical lubricants, topical steroids and systemic diuretics to prevent the development of corneal toxicity, ocular chemosis and swelling, which can potentially be associated with the use of the targeted agents. Overall, the management of targeted therapy-induced ocular complications requires a close partnership between ophthalmologists and oncologists. Most patients with mild toxicities do not require treatments other than lubrication or eye patching, while the cessation of the offending targeted agents will usually lead to clinical improvement in more severe cases. Some of these simple measures may be managed by oncologists alone. For more complicated patients, ophthalmological input is indicated so that more attentive eye care and follow-ups can be arranged. Specific treatments exist for different conditions: for instance, diuretics for periorbital oedema (McClelland et al. 2010), steroids for optic neuritis (Govind Babu et al. 2007) and anti-microbials for secondary infections (Fraunfelder et al. 2003). Novel therapies, such as topical application of human EGF, which binds in and stimulates migration of corneal epithelial have been used to treat corneal erosion et al. 2008). In rare treatment is surgical debulking was reported in the treatment of severe oedema causing visual (Biswas et al. 2009). For patients these of treatment, follow-up by an is (Table 2). The ocular effects of targeted agents are and ophthalmologists are to an increasing number of from the oncologists for the management of these side-effects. ophthalmologists should be in these complications promptly.
No takes yet. Share an insight, caveat, or question.
Ho et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: